Thursday, January 19, 2012
Rexahn Pharmaceuticals Inc., of Rockville, Md., received approval from the Hungarian Regulatory Authority and Ethics Committee for its initial clinical trial application to begin a Phase I trial of RX-3117. Preclinical studies showed anticancer activity. The company plans to explore its potential in a broad range of cancers including colon, lung and pancreatic.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.